Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.

MLA

Carlson, Anders L., et al. “Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.” Diabetes Technology & Therapeutics, vol. 24, no. 3, Mar. 2022, pp. 178–89. EBSCOhost, https://doi.org/10.1089/dia.2021.0319.

APA

Carlson, A. L., Sherr, J. L., Shulman, D. I., Garg, S. K., Pop-Busui, R., Bode, B. W., Lilenquist, D. R., Brazg, R. L., Kaiserman, K. B., Kipnes, M. S., Thrasher, J. R., Reed, J. H. C., Slover, R. H., Philis-Tsimikas, A., Christiansen, M., Grosman, B., Roy, A., Vella, M., Jonkers, R. A. M., … Vigersky, R. A. (2022). Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics, 24(3), 178–189. https://doi.org/10.1089/dia.2021.0319

Chicago

Carlson, Anders L, Jennifer L Sherr, Dorothy I Shulman, Satish K Garg, Rodica Pop-Busui, Bruce W Bode, David R Lilenquist, et al. 2022. “Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.” Diabetes Technology & Therapeutics 24 (3): 178–89. doi:10.1089/dia.2021.0319.